Atorvastatin reduces serum HMGB1 levels in patients with hyperlipidemia

Experimental and Therapeutic Medicine

Volumn 4, Issue 6, 2012, Pages 1124-1126

  Jin, Daoqun ^a   Wu, Yongbo ^a   Zhao, Lin ^a   Guo, Jie ^a   Zhang, Kai ^a   Chen, Zhiqiang ^a  

^a Central Hospital of Huangshi   (China)

Author keywords

Atorvastatin; High mobility group box 1 protein; Hyperlipidemia; Inflammation

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH MOBILITY GROUP B1 PROTEIN; HIGH SENSITIVITY C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84867245259     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.732     Document Type: Article

References (21)

1. Libby P, Ridker PM and Maseri A: Inflammation and athero - sclerosis. Circulation 105: 1135-1143, 2002.
2. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695, 2005.
3. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, et al: Clinical utility of different lipid measures for prediction of heart disease in men and women. JAMA 298: 776-785, 2007.
4. Siasos G, Tousoulis D, Oikonomou E, Zaromitidou M, Stefanad C and Papavassiliou AG: Inflammatory markers in hyperlipidemia: from experimental models to clinical practice. Curr Pharm Des 17: 4132-4146, 2011.
5. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251, 1999.
6. Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195, 2002.
7. Yan XX, Lu L, Peng WH, Wang LJ, Zhang Q, Zhang RY, et al: Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 205: 544-548, 2009.
8. Hu X, Jiang H, Bai Q, Zhou X, Xu C, Lu Z, et al: Increased serum HMGB1 is related to the severity of coronary artery stenosis. Clin Chim Acta 406: 139-142, 2009.
9. Ding HS and Yang J: High mobility group box-1 and cardio - vascular diseases. Saudi Med J 31: 486-489, 2010.
10. Kohno T, Anzai T, Naito K, Miyasho T, Okamoto K, Yokota H, et al: Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovasc Res 81: 565-573, 2009.
11. Haraba R, Suica VI, Uyy E, Ivan L and Antohe F: Hyperlipidemia stimulates the extracellular release of the nuclear high mobility group box 1 protein. Cell Tissue Res 346: 361-368, 2011.
12. Kalinina N, Agrotis A, Antropova Y, DiVitto G, Kanellakis P, Kostolias G, et al: Increased expression of the DNA binding cytokine HMGB1 in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 24: 2320-2325, 2004.
13. Inoue K, Kawahara KI, Krishna K, Ando K, Mitsudo K, Nobuyoshi M and Maruyama I: HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 16: 136-143, 2007.
14. Niccoli G, Biasucci LM, Biscione, Fusco B, Porto I, Leone AM, et al: Independent prognostic value of C-reactive protein and coronary artery disease extent in patients affected by unstable angina. Atherosclerosis 196: 779-785, 2008.
15. Arroyo-Espliguero R, Avanzas P, Quiles J and Kaski JC: Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease. Atherosclerosis 204: 239-243, 2009.
16. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W and Szczeklik A: Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 77: 247-253, 2001.
17. Ascer E, Bertolami MC, Venturinelli ML, Buccheri V, Souza J, Nicolau JC, et al: Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 177: 161-166, 2004.
18. Hu X, Fu W and Jiang H: HMGB1: A potential therapeutic target for myocardial ischemia and reperfusion injury. Int J Cardiol 155: 489-489, 2012.
19. Wang L, Zhang X, Liu L, Yang R, Cui L and Li M: Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF-kappaB expression. Neurosci Lett 471: 152-156, 2010.
20. Yang J, Huang C, Yang J, Jiang H and Ding J: Statins attenuate high mobility group box-1 protein-induced vascular endothelial activation: a key role for TLR4/NF-κB signaling pathway. Mol Cell Biochem 345: 189-195, 2010.
21. Blumenthal RS and Boltlmore MD: Statins: effective antiatherosclerotic therapy. Am Heart J 139: 577-583, 2000.